Inclusion Criteria:

- Male or female patients with CD23+, CD5+, CD19+ light chain monoclonal B-CLL with
treatment indication according to IWCLL criteria (Appendix 4)

- 1st or greater relapse after fludarabine or any other primary treatment regimen OR
Refractory to any previous treatment and simultaneous indication for treatment
according to IWCLL criteria (Appendix 4)

- Age 18 years and older

- ECOG status 0 - 2

- Life expectancy > 6 months

- Written informed consent given by the patient

- Patient using a reliable means of contraception (e.g. physical barrier, contraceptive
pill or patch, spermicide and barrier, or IUD) for the duration of the study. Male
patients have to use an adequate contraception method for the duration of study
treatment and for 6 months following completion of study treatment. Women of
childbearing potential have to use an effective method of contraception for the
duration of study participation.

Exclusion Criteria:

- HIV positive or positive for Hepatitis B or C

- Active uncontrolled infection

- Pregnant or lactating women

- Hypersensitivity with anaphylactic reaction to humanised monoclonal antibodies or to
the excipients of any of the applied drugs (e.g. Bendamustine hydrochloride or
mannitol)

- Previous treatment with bendamustine

- Treatment with an experimental drug within the previous 2 months

- Patients with a history of other malignancies within 2 years prior to study entry,
except for adequately treated carcinoma in situ of the cervix; basal or squamous cell
skin cancer; low grade, early stage localized prostate cancer treated surgically with
curative intent; good prognosis DCIS of the breast treated with lumpectomy alone with
curative intent.

- Transformation to aggressive B-cell malignancy (e.g. large B-cell lymphoma, Richter's
syndrome, or prolymphocytic leukemia (PLL)

- Decreased kidney function with creatinine clearance < 30 ml/min

- Patients with severe co-morbidities or major organ dysfunctions (e.g. known severe
liver damage, jaundice)

- Patients with a history of severe cardiac disease; e.g. NYHA Functional Class III or
IV heart failure, myocardial infarction within 6 months, ventricular tachyarrhythmias
requiring ongoing treatment, or unstable angina

- Any co-existing medical or psychological condition that would preclude participation
in the study or compromise ability to give informed consent, or patients unable to
comply with requirements of study protocol